Alpine Associates Management Inc. cut its holdings in NxStage Medical, Inc. (NASDAQ:NXTM) by 9.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,023,671 shares of the medical device company’s stock after selling 303,311 shares during the period. NxStage Medical comprises about 2.3% of Alpine Associates Management Inc.’s holdings, making the stock its 17th largest position. Alpine Associates Management Inc. owned about 4.61% of NxStage Medical worth $84,331,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its position in shares of NxStage Medical by 25.5% in the 3rd quarter. Janus Henderson Group PLC now owns 10,505 shares of the medical device company’s stock worth $293,000 after buying an additional 2,134 shares in the last quarter. Rhumbline Advisers boosted its position in shares of NxStage Medical by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 67,450 shares of the medical device company’s stock worth $1,882,000 after buying an additional 2,250 shares in the last quarter. Public Employees Retirement Association of Colorado boosted its position in shares of NxStage Medical by 63.8% in the 3rd quarter. Public Employees Retirement Association of Colorado now owns 8,635 shares of the medical device company’s stock worth $241,000 after buying an additional 3,362 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of NxStage Medical in the 2nd quarter worth about $122,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of NxStage Medical by 714.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 80.83% of the company’s stock.
Several equities research analysts recently commented on NXTM shares. BidaskClub upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. ValuEngine upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, October 12th. Finally, Zacks Investment Research upgraded shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th.
NxStage Medical (NASDAQ:NXTM) last released its earnings results on Wednesday, November 7th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.03. The company had revenue of $108.12 million for the quarter, compared to analyst estimates of $108.07 million. NxStage Medical had a negative net margin of 1.29% and a negative return on equity of 2.50%. As a group, equities research analysts predict that NxStage Medical, Inc. will post -0.02 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Alpine Associates Management Inc. Sells 303,311 Shares of NxStage Medical, Inc. (NXTM)” was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/11/23/alpine-associates-management-inc-sells-303311-shares-of-nxstage-medical-inc-nxtm.html.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Read More: The Structure of a Futures Contract
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.